Union Korea Pharm Amends Listing Date of Rehabilitation Shares to July 29; 650% Dilution Remains Unchanged
Union Korea Pharm filed an amendment on July 14, 2026, adjusting the listing date of new shares issued via debt-to-equity swap to July 29, 2026, due to administrative delays at the depository.
This amendment only modifies the listing schedule; key terms remain unchanged: 51.66 million new shares issued at 500 KRW per share, resulting in approximately 650% dilution for existing shareholders.
The capital increase is a debt repayment measure under the rehabilitation plan, with no new cash inflow. The largest shareholder will change to Park Kwang-seok and others. Existing shareholders face severe value dilution.
[AI Summary]This amendment is purely administrative and does not alter the fundamental dilution impact of the rehabilitation plan. The 650% dilution and 82% discount to market price continue to pose significant negative pressure on shareholder value. Investors should remain cautious.
KOSDAQ Filing Information
[Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)